Lubov V. Radygina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lubov V. Radygina has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Larisa V. Mochalova
Всероссийский институт научной и технической информации Российской академии наук, ул. Усиевича, 20, Москва, 125315 Россия
6 shared publications - M. N. Barybkina
All-Russian Institute of Scientific and Technical Information
1 shared publication Л. В. Радыгина
Всероссийский институт научной и технической информации
1 shared publicationМ. Н. Барыбкина
Всероссийский институт научной и технической информации
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Open Systems Publications in Лечащий врач
- No. 9(29),p. 39-43
Systemic lupus erythematosus and angiogenesis: clinical aspects and approaches to therapy
Background. Systemic lupus erythematosus is an autoimmune disease with a multifaceted pathogenesis. Objective. To evaluate the role of angiogenesis in the diagnosis and treatment of systemic lupus erythematosus. Materials and methods. A systematic review of the scientific literature from 2000 to 2025 was conducted using PubMed, Scopus, and Web of Science databases. Results. Angiogenesis and microvascular endothelial damage play a role in the pathogenesis of systemic lupus erythematosus. Vascular endothelial growth factor, hepatocyte growth factor, stromal cell-derived factor-1, placental growth factor, chemokines, and interleukin-17F are elevated in patients with systemic lupus erythematosus, especially during the active phase of the disease. Measuring serum MFG-E8 levels in patients with systemic lupus erythematosus may be useful for assessing the risk of cerebrovascular disease or neuropsychiatric manifestations associated with these diseases. Angiogenesis can also be assessed using the in vitro Matrigel vascular tube formation assay and nailfold capillaroscopy. Patients with systemic lupus erythematosus experience accelerated atherosclerosis, significantly increasing the risk of cardiovascular complications. Endothelial dysfunction, one of the first stages of atherogenesis, is detected in patients with systemic lupus erythematosus even in the absence of a history of cardiovascular disease. It has been established that testing for impaired angiogenesis has demonstrated high efficacy in the diagnosis of systemic lupus erythematosus. Vitamin D, exosomes, and mesenchymal stem cells can be used to treat systemic lupus erythematosus. Approaches to systemic lupus erythematosus therapy that take into account impaired angiogenesis are a promising direction. Conclusion. Research into impaired angiogenesis offers broad prospects for individualizing diagnostic and therapeutic approaches. However, implementing these methods into clinical practice requires the development of unified standards and large-scale studies at multiple centers.
- 24 September 2026
- Published by Open Systems Publications in Лечащий врач
- No. 9(29),p. 39-43
Open AccessSystemic lupus erythematosus and angiogenesis: clinical aspects and approaches to therapy
Background. Systemic lupus erythematosus is an autoimmune disease with a multifaceted pathogenesis. Objective. To evaluate the role of angiogenesis in the diagnosis and treatment of systemic lupus erythematosus. Materials and methods. A systematic review of the scientific literature from 2000 to 2025 was conducted using PubMed, Scopus, and Web of Science databases. Results. Angiogenesis and microvascular endothelial damage play a role in the pathogenesis of systemic lupus erythematosus. Vascular endothelial growth factor, hepatocyte growth factor, stromal cell-derived factor-1, placental growth factor, chemokines, and interleukin-17F are elevated in patients with systemic lupus erythematosus, especially during the active phase of the disease. Measuring serum MFG-E8 levels in patients with systemic lupus erythematosus may be useful for assessing the risk of cerebrovascular disease or neuropsychiatric manifestations associated with these diseases. Angiogenesis can also be assessed using the in vitro Matrigel vascular tube formation assay and nailfold capillaroscopy. Patients with systemic lupus erythematosus experience accelerated atherosclerosis, significantly increasing the risk of cardiovascular complications. Endothelial dysfunction, one of the first stages of atherogenesis, is detected in patients with systemic lupus erythematosus even in the absence of a history of cardiovascular disease. It has been established that testing for impaired angiogenesis has demonstrated high efficacy in the diagnosis of systemic lupus erythematosus. Vitamin D, exosomes, and mesenchymal stem cells can be used to treat systemic lupus erythematosus. Approaches to systemic lupus erythematosus therapy that take into account impaired angiogenesis are a promising direction. Conclusion. Research into impaired angiogenesis offers broad prospects for individualizing diagnostic and therapeutic approaches. However, implementing these methods into clinical practice requires the development of unified standards and large-scale studies at multiple centers.
- Open Access
- 1 January 2024
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 11 (1) , 57-69
Diseases caused by human T-lymphotropic virus type 1 (HTLV-1)
INTRODUCTION: Human T-lymphotropic virus type 1 (HTLV-1) belongs to the Retroviridae family (genus Deltaretrovirus) and is directly involved in carcinogenesis. The HTLV-1 genome is represented by plus-strand RNA, which is transcribed into proviral DNA and then integrated into the genome of the host cell. After integration, HTLV-1 is present in the cells in the form of a provirus. As in the case of the human immunodeficiency virus, the main targets of HTLV-1 are CD4+ T lymphocytes. The virus is transmitted sexually, through blood transfusion, and breastfeeding by biological fluids – sperm, blood, and breast milk. The epidemiology of HTLV-1 remains a mystery: clusters of high endemicity are often located near areas where the virus is virtually absent. AIM: To analyze and discuss the clinical picture, diagnostics, and treatment of diseases caused by HTLV-1. METHODS: A literature search was conducted in the databases PubMed, eLIBRARY.ru, and cyberleninka.ru using the keywords: “HTLV-1” + “diseases”, “HTLV-1” + “diagnosis”, “HTLV-1” + “epidemiology”, “HTLV-1” + “treatment”, “HTLV-1” + “Russia” in English and Russian languages. The primary search was conducted for papers published in 2020–2024. RESULTS: HTLV-1 infection is associated with diseases such as T-cell leukemia/lymphoma and myelopathy/tropical spastic paraparesis. HTLV-1 infection causes pathologies in most organs of the human body. Because diseases associated with HTLV-1 are most often asymptomatic, etiological diagnoses are performed at the stage of pathological development or when screening donor blood for pathogens. CONCLUSION: In this review, we analyzed and discussed the clinical manifestations and course of diseases caused by HTLV-1, their diagnosis, and treatment. The lack of reliable population-based studies on the prevalence of this virus is alarming. In fact, HTLV-1 is diagnosed only in blood donors and pregnant women. Currently, this virus is considered endemic to several territories (Africa, Australia, the Middle East, Japan, etc.) and some indigenous peoples. However, we consider it important to draw the attention of both epidemiologists and clinicians to HTLV-1, given the unprecedented migration flows and international connections in the modern world.
- 1 January 2024
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 11 (1) , 57-69
Open AccessDiseases caused by human T-lymphotropic virus type 1 (HTLV-1)
INTRODUCTION: Human T-lymphotropic virus type 1 (HTLV-1) belongs to the Retroviridae family (genus Deltaretrovirus) and is directly involved in carcinogenesis. The HTLV-1 genome is represented by plus-strand RNA, which is transcribed into proviral DNA and then integrated into the genome of the host cell. After integration, HTLV-1 is present in the cells in the form of a provirus. As in the case of the human immunodeficiency virus, the main targets of HTLV-1 are CD4+ T lymphocytes. The virus is transmitted sexually, through blood transfusion, and breastfeeding by biological fluids – sperm, blood, and breast milk. The epidemiology of HTLV-1 remains a mystery: clusters of high endemicity are often located near areas where the virus is virtually absent. AIM: To analyze and discuss the clinical picture, diagnostics, and treatment of diseases caused by HTLV-1. METHODS: A literature search was conducted in the databases PubMed, eLIBRARY.ru, and cyberleninka.ru using the keywords: “HTLV-1” + “diseases”, “HTLV-1” + “diagnosis”, “HTLV-1” + “epidemiology”, “HTLV-1” + “treatment”, “HTLV-1” + “Russia” in English and Russian languages. The primary search was conducted for papers published in 2020–2024. RESULTS: HTLV-1 infection is associated with diseases such as T-cell leukemia/lymphoma and myelopathy/tropical spastic paraparesis. HTLV-1 infection causes pathologies in most organs of the human body. Because diseases associated with HTLV-1 are most often asymptomatic, etiological diagnoses are performed at the stage of pathological development or when screening donor blood for pathogens. CONCLUSION: In this review, we analyzed and discussed the clinical manifestations and course of diseases caused by HTLV-1, their diagnosis, and treatment. The lack of reliable population-based studies on the prevalence of this virus is alarming. In fact, HTLV-1 is diagnosed only in blood donors and pregnant women. Currently, this virus is considered endemic to several territories (Africa, Australia, the Middle East, Japan, etc.) and some indigenous peoples. However, we consider it important to draw the attention of both epidemiologists and clinicians to HTLV-1, given the unprecedented migration flows and international connections in the modern world.
- Open Access
- 1 January 2024
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 11 (1) , 57-69
Заболевания, ассоциированные с Т-лимфотропным вирусом типа 1 человека (HTLV-1)
ВВЕДЕНИЕ: Т-лимфотропный вирус типа 1 человека (HTLV-1) относится к семейству Retroviridae (род Deltaretrovirus) и напрямую участвует в канцерогенезе. Геном HTLV-1 представлен плюс-цепью РНК, которая транскрибируется в провирусную ДНК, а затем встраивается в геном клетки хозяина. После интеграции HTLV-1 присутствует в клетке в форме провируса. Как и для вируса иммунодефицита человека, основными мишенями HTLV-1 служат CD4 + T-лифоциты. Вирус передается через биологические жидкости организма: сперму, кровь и грудное молоко, – то есть половым путем, при гемотрансфузии и грудном вскармливании. Что касается эпидемиологии HTLV-1, то она до сих пор остается загадкой: кластеры с высокой эндемичностью часто расположены вблизи районов, где вирус практически отсутствует. ЦЕЛЬ: Проанализировать клиническую картину, диагностику и лечение заболеваний, вызванных HTLV-1. МЕТОДЫ: Проведен поиск литературы в базах PubMed, elibrary.ru и cyberleninka.ru по ключевым словам: «HTLV-1»+«diseases», «HTLV-1»+«diagnosis», «HTLV-1»+«epidemiology», «HTLV-1»+«treatment», «HTLV-1»+«Russia»; «HTLV-1»+«болезни», «HTLV-1»+«диагностика», «HTLV-1»+«эпидемиология», «HTLV-1»+«лечение», «HTLV-1»+«Россия». Основной поиск проведен за 2020–2024 гг. РЕЗУЛЬТАТЫ: С HTLV-1 связаны такие заболевания, как Т-клеточный лейкоз/лимфома и миелопатия/тропический спастический парапарез. При HTLV-1-инфекции регистрируют патологии большинства систем органов. В связи с тем, что ассоциированные с HTLV-1 заболевания чаще всего протекают бессимптомно, этиологическую диагностику проводят уже на стадии развития патологии или при скрининге крови доноров на патогены. ЗАКЛЮЧЕНИЕ: В обзоре рассмотрены вопросы клинических проявлений и течения заболеваний, вызванных HTLV-1, их диагностики и лечения. Несколько настораживает отсутствие серьезных популяционных исследований по распространенности этого вируса – фактически, диагностика на HTLV-1 предусмотрена только у доноров и у беременных. До сих пор этот вирус считается эндемичным для ряда территорий (Африка, Австралия, Ближний Восток, Япония и др.) и некоторых коренных народов, но, учитывая беспрецедентные миграционные потоки и международные связи в современном мире, мы считаем важным привлечь к нему внимание как эпидемиологов, так и клиницистов. INTRODUCTION: Human T-lymphotropic virus type 1 (HTLV-1) belongs to the Retroviridae family (genus Deltaretrovirus) and is directly involved in carcinogenesis. The HTLV-1 genome is represented by plus-strand RNA, which is transcribed into proviral DNA and then integrated into the genome of the host cell. After integration, HTLV-1 is present in the cells in the form of a provirus. As in the case of the human immunodeficiency virus, the main targets of HTLV-1 are CD4 + T lymphocytes. The virus is transmitted sexually, through blood transfusion, and breastfeeding by biological fluids - sperm, blood, and breast milk. The epidemiology of HTLV-1 remains a mystery: clusters of high endemicity are often located near areas where the virus is virtually absent. AIM: To analyze and discuss the clinical picture, diagnostics, and treatment of diseases caused by HTLV-1. METHODS: A literature search was conducted in the databases PubMed, eLIBRARY.ru, and cyberleninka.ru using the keywords: “HTLV-1” + “diseases”, “HTLV-1” + “diagnosis”, “HTLV-1” + “epidemiology”, “HTLV-1” + “treatment”, “HTLV-1” + “Russia” in English and Russian languages. The primary search was conducted for papers published in 2020–2024. RESULTS: HTLV-1 infection is associated with diseases such as T-cell leukemia/lymphoma and myelopathy/tropical spastic paraparesis. HTLV-1 infection causes pathologies in most organs of the human body. Since diseases associated with HTLV-1 are most often asymptomatic, etiological diagnoses are performed at the stage of pathological development or when screening donor blood for pathogens. CONCLUSION: In this review, we analyze and discuss the clinical manifestations and course of diseases caused by HTLV-1, their diagnosis and treatment. The lack of reliable population-based studies on the prevalence of this virus is alarming. In fact, the diagnosis of HTLV-1 is provided only for blood donors and pregnant women. Currently, this virus is considered endemic to several territories (Africa, Australia, the Middle East, Japan, etc.) and some indigenous peoples. However, we consider it important to draw the attention of both epidemiologists and clinicians to HTLV-1, given the unprecedented migration flows and international connections in the modern world.
- 1 January 2024
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 11 (1) , 57-69
Open AccessЗаболевания, ассоциированные с Т-лимфотропным вирусом типа 1 человека (HTLV-1)
ВВЕДЕНИЕ: Т-лимфотропный вирус типа 1 человека (HTLV-1) относится к семейству Retroviridae (род Deltaretrovirus) и напрямую участвует в канцерогенезе. Геном HTLV-1 представлен плюс-цепью РНК, которая транскрибируется в провирусную ДНК, а затем встраивается в геном клетки хозяина. После интеграции HTLV-1 присутствует в клетке в форме провируса. Как и для вируса иммунодефицита человека, основными мишенями HTLV-1 служат CD4 + T-лифоциты. Вирус передается через биологические жидкости организма: сперму, кровь и грудное молоко, – то есть половым путем, при гемотрансфузии и грудном вскармливании. Что касается эпидемиологии HTLV-1, то она до сих пор остается загадкой: кластеры с высокой эндемичностью часто расположены вблизи районов, где вирус практически отсутствует. ЦЕЛЬ: Проанализировать клиническую картину, диагностику и лечение заболеваний, вызванных HTLV-1. МЕТОДЫ: Проведен поиск литературы в базах PubMed, elibrary.ru и cyberleninka.ru по ключевым словам: «HTLV-1»+«diseases», «HTLV-1»+«diagnosis», «HTLV-1»+«epidemiology», «HTLV-1»+«treatment», «HTLV-1»+«Russia»; «HTLV-1»+«болезни», «HTLV-1»+«диагностика», «HTLV-1»+«эпидемиология», «HTLV-1»+«лечение», «HTLV-1»+«Россия». Основной поиск проведен за 2020–2024 гг. РЕЗУЛЬТАТЫ: С HTLV-1 связаны такие заболевания, как Т-клеточный лейкоз/лимфома и миелопатия/тропический спастический парапарез. При HTLV-1-инфекции регистрируют патологии большинства систем органов. В связи с тем, что ассоциированные с HTLV-1 заболевания чаще всего протекают бессимптомно, этиологическую диагностику проводят уже на стадии развития патологии или при скрининге крови доноров на патогены. ЗАКЛЮЧЕНИЕ: В обзоре рассмотрены вопросы клинических проявлений и течения заболеваний, вызванных HTLV-1, их диагностики и лечения. Несколько настораживает отсутствие серьезных популяционных исследований по распространенности этого вируса – фактически, диагностика на HTLV-1 предусмотрена только у доноров и у беременных. До сих пор этот вирус считается эндемичным для ряда территорий (Африка, Австралия, Ближний Восток, Япония и др.) и некоторых коренных народов, но, учитывая беспрецедентные миграционные потоки и международные связи в современном мире, мы считаем важным привлечь к нему внимание как эпидемиологов, так и клиницистов. INTRODUCTION: Human T-lymphotropic virus type 1 (HTLV-1) belongs to the Retroviridae family (genus Deltaretrovirus) and is directly involved in carcinogenesis. The HTLV-1 genome is represented by plus-strand RNA, which is transcribed into proviral DNA and then integrated into the genome of the host cell. After integration, HTLV-1 is present in the cells in the form of a provirus. As in the case of the human immunodeficiency virus, the main targets of HTLV-1 are CD4 + T lymphocytes. The virus is transmitted sexually, through blood transfusion, and breastfeeding by biological fluids - sperm, blood, and breast milk. The epidemiology of HTLV-1 remains a mystery: clusters of high endemicity are often located near areas where the virus is virtually absent. AIM: To analyze and discuss the clinical picture, diagnostics, and treatment of diseases caused by HTLV-1. METHODS: A literature search was conducted in the databases PubMed, eLIBRARY.ru, and cyberleninka.ru using the keywords: “HTLV-1” + “diseases”, “HTLV-1” + “diagnosis”, “HTLV-1” + “epidemiology”, “HTLV-1” + “treatment”, “HTLV-1” + “Russia” in English and Russian languages. The primary search was conducted for papers published in 2020–2024. RESULTS: HTLV-1 infection is associated with diseases such as T-cell leukemia/lymphoma and myelopathy/tropical spastic paraparesis. HTLV-1 infection causes pathologies in most organs of the human body. Since diseases associated with HTLV-1 are most often asymptomatic, etiological diagnoses are performed at the stage of pathological development or when screening donor blood for pathogens. CONCLUSION: In this review, we analyze and discuss the clinical manifestations and course of diseases caused by HTLV-1, their diagnosis and treatment. The lack of reliable population-based studies on the prevalence of this virus is alarming. In fact, the diagnosis of HTLV-1 is provided only for blood donors and pregnant women. Currently, this virus is considered endemic to several territories (Africa, Australia, the Middle East, Japan, etc.) and some indigenous peoples. However, we consider it important to draw the attention of both epidemiologists and clinicians to HTLV-1, given the unprecedented migration flows and international connections in the modern world.
- Open Access
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 70-90
Biological markers of sepsis
Currently, the issues of early sepsis diagnosis, assessment of the effectiveness of therapies conducted, and disease prognosis are extremely relevant. In the case of sepsis, timely medical assistance is complicated by the ambiguity of symptoms and the absence of a specific diagnostic test. Therefore, the search for sepsis biomarkers with diagnostic, prognostic, and therapeutic potential is underway in medical centers worldwide. This review summarizes research results regarding the diagnostic values of sepsis biomarkers – their sensitivity, specificity, and prognostic value – as presented in scientific publications indexed in international databases.
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 70-90
Open AccessBiological markers of sepsis
Currently, the issues of early sepsis diagnosis, assessment of the effectiveness of therapies conducted, and disease prognosis are extremely relevant. In the case of sepsis, timely medical assistance is complicated by the ambiguity of symptoms and the absence of a specific diagnostic test. Therefore, the search for sepsis biomarkers with diagnostic, prognostic, and therapeutic potential is underway in medical centers worldwide. This review summarizes research results regarding the diagnostic values of sepsis biomarkers – their sensitivity, specificity, and prognostic value – as presented in scientific publications indexed in international databases.
- Open Access
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 70-90
Биологические маркеры сепсиса
В настоящее время проблема ранней диагностики сепсиса, оценки эффективности проводимой терапии и прогноза течения заболевания крайне актуальна. При сепсисе своевременное оказание медицинской помощи осложнено нечеткостью симптомов и отсутствием специфического диагностического теста. В связи с этим во всем мире ведется поиск биологических маркеров сепсиса: диагностических, прогностических и терапевтических. В обзоре суммированы результаты исследований по диагностической ценности биологических маркеров сепсиса, их чувствительности, специфичности и прогностической ценности из научных публикаций, представленных в международных базах данных.
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 70-90
Open AccessБиологические маркеры сепсиса
В настоящее время проблема ранней диагностики сепсиса, оценки эффективности проводимой терапии и прогноза течения заболевания крайне актуальна. При сепсисе своевременное оказание медицинской помощи осложнено нечеткостью симптомов и отсутствием специфического диагностического теста. В связи с этим во всем мире ведется поиск биологических маркеров сепсиса: диагностических, прогностических и терапевтических. В обзоре суммированы результаты исследований по диагностической ценности биологических маркеров сепсиса, их чувствительности, специфичности и прогностической ценности из научных публикаций, представленных в международных базах данных.
- Open Access
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 20-38
Factors affecting the severity of COVID-19 and the development of complications
Due to the prevalence and diversity of both symptoms and outcomes of COVID-19, understanding the factors that determine the risk of the severe course of this disease and its possible complications is of particular importance. In this review, we present the information on the specifics of COVID-19 pathogenesis and give a theoretical justification for the factors that determine the course of this disease in patients of different age groups, patients with chronic pathology, and pregnant women. Particular attention is paid to the post-COVID syndrome.
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 20-38
Open AccessFactors affecting the severity of COVID-19 and the development of complications
Due to the prevalence and diversity of both symptoms and outcomes of COVID-19, understanding the factors that determine the risk of the severe course of this disease and its possible complications is of particular importance. In this review, we present the information on the specifics of COVID-19 pathogenesis and give a theoretical justification for the factors that determine the course of this disease in patients of different age groups, patients with chronic pathology, and pregnant women. Particular attention is paid to the post-COVID syndrome.
- Open Access
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 20-38
Факторы, влияющие на тяжесть течения COVID-19 и развитие осложнений
В связи с широким распространением и «многоликостью» как симптоматики, так и исходов COVID-19 особую актуальность приобретает понимание факторов, определяющих риск тяжелого течения заболевания и возможных осложнений. В обзоре представлена информация об особенностях патогенеза COVID-19, дали теоретическое обоснование факторов, обусловливающих особенности заболевания у пациентов разных возрастных групп, беременных, а также при хронических патологиях. Отдельное внимание уделено постковидному синдрому.
- 1 January 2023
- Published by Doctrine in Microbiology Independent Research Journal (MIR Journal)
- Vol. 10 (1) , 20-38
Open AccessФакторы, влияющие на тяжесть течения COVID-19 и развитие осложнений
В связи с широким распространением и «многоликостью» как симптоматики, так и исходов COVID-19 особую актуальность приобретает понимание факторов, определяющих риск тяжелого течения заболевания и возможных осложнений. В обзоре представлена информация об особенностях патогенеза COVID-19, дали теоретическое обоснование факторов, обусловливающих особенности заболевания у пациентов разных возрастных групп, беременных, а также при хронических патологиях. Отдельное внимание уделено постковидному синдрому.